Insider Trading March 9, 2026

Quantum-Si Director Paula Dowdy Acquires 109,890 Class A Shares in March Transaction

Purchase of roughly $104,450 adds to Dowdy's stake as the stock trades near its 52-week low and recent earnings missed revenue expectations

By Hana Yamamoto QSI
Quantum-Si Director Paula Dowdy Acquires 109,890 Class A Shares in March Transaction
QSI

Quantum-Si Inc. director Paula Dowdy bought 109,890 shares of the company’s Class A common stock on March 5, 2026, investing $104,450 at a weighted average price of $0.9505. After the purchase, Dowdy directly holds 269,107 shares. The trade occurred while QSI shares were trading around $0.86, close to a 52-week low of $0.84. Recent company results for the fourth quarter of 2025 showed EPS that beat expectations but revenue that fell short, prompting an analyst firm to cut its price target and keep a Hold rating.

Key Points

  • Quantum-Si director Paula Dowdy purchased 109,890 Class A shares on March 5, 2026, for a total of $104,450 at a weighted average price of $0.9505.
  • Following the purchase, Dowdy directly owns 269,107 shares; the trade happened while QSI traded at about $0.86, near its 52-week low of $0.84, with a reported one-week decline of 7.7% and a market cap of $186 million.
  • Quantum-Si’s Q4 2025 results were mixed: EPS of -$0.08 beat expectations of -$0.12, while revenue of $451,000 missed the $761,900 forecast; Canaccord cut its price target to $1.00 but kept a Hold rating, citing low-single-digit Platinum instrument sales and roughly 27% gross margins.

Transaction details

According to a Form 4 filing with the Securities and Exchange Commission, Paula Dowdy, a director at Quantum-Si Inc., acquired 109,890 shares of Class A common stock on March 5, 2026. The total consideration for the purchase was $104,450, with a weighted average purchase price of $0.9505 per share. The filing indicates individual execution prices ranged from $0.9051 to $0.9730. Following the acquisition, Dowdy is recorded as directly owning 269,107 shares of Quantum-Si.

Market context at the time of the trade

The insider purchase took place while QSI shares were trading near $0.86, a level slightly above the 52-week low of $0.84. Market data cited alongside the filing noted a one-week decline in the stock of 7.7% and a market capitalization for the company of $186 million. A valuation reference from InvestingPro listed a Fair Value of $1.22 for QSI, implying a potential difference versus prevailing market levels.

Recent operating and analyst developments

Quantum-Si reported fourth-quarter results for 2025 that were mixed. The company recorded an earnings per share loss of $0.08, which was ahead of analyst expectations of a $0.12 loss. Revenue, however, missed forecasts, coming in at $451,000 versus an anticipated $761,900. In response to the quarter, Canaccord adjusted its price target for Quantum-Si shares from $1.50 to $1.00 while maintaining a Hold rating. The firm highlighted that sales of the company’s Platinum instruments were in the low-single-digit units range and that those instruments generated a gross margin around 27%.


What the filing shows and what remains unchanged

The Form 4 documents the specifics of Dowdy’s placement of capital into Quantum-Si Class A common stock without offering commentary on motivation or future intent. The broader financial disclosure from the company for Q4 2025 and the analyst action from Canaccord provide contemporaneous context for the trade, but the filing itself contains only the transactional facts outlined above.

Summary of the facts

  • Purchase date: March 5, 2026.
  • Shares purchased: 109,890 Class A common shares.
  • Total invested: $104,450; weighted average price: $0.9505; price range: $0.9051 to $0.9730.
  • Post-transaction direct ownership for Paula Dowdy: 269,107 shares.
  • QSI trading context: trading at $0.86, 52-week low $0.84, one-week decline of 7.7%, market cap reported at $186 million.
  • Recent quarterly results: Q4 2025 EPS of -$0.08 versus -$0.12 expected; revenue $451,000 versus $761,900 expected.
  • Analyst action: Canaccord cut its price target from $1.50 to $1.00 and maintained a Hold rating; reported low-single-digit sales of Platinum instruments and roughly 27% gross margin for those sales.

Risks

  • Revenue for Q4 2025 missed analyst expectations, which represents a near-term operational risk for the company and could affect investor sentiment in the biotech and capital markets sectors.
  • The stock was trading close to its 52-week low and had declined 7.7% over the prior week, indicating volatility and downside risk for shareholders in the short term.
  • Analyst actions such as Canaccord lowering its price target to $1.00 while maintaining a Hold rating reflect continued uncertainty about near-term commercial traction and financial performance, relevant to investors focused on valuation and execution in the biotech sector.

More from Insider Trading

Foxx Development EVP Disposes of 759 Shares in Two Trades; Company Reports Board Addition Mar 20, 2026 Natera Co-Founder Sells $908,301 in Stock as Analysts Weigh In on Valuation and Growth Signals Mar 20, 2026 GigaCloud director Wu Lei disposes of $2.45M in Class A shares as 10b5-1 plan closes Mar 20, 2026 Alpha Metallurgical Resources Director Adds $1.53M in Stock Through Multiple Purchases Mar 20, 2026 Indie Semiconductor President Disposes of $388K in Class A Shares Amid Strategic Financing and Partnership Moves Mar 20, 2026